3-rx.comCustomer Support
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics

\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>

Join our Mailing List


You are here : 3-RX.com > Home > Diabetes - Drug News - Eye / Vision Problems -

Drug shows promise against diabetic eye condition

Diabetes • • Drug News • • Eye / Vision ProblemsJan 03, 07

Eye injections of the drug Lucentis (also known as ranibizumab) appear to be useful in the treatment of a potentially blinding eye condition called macular edema that can afflict people with diabetes, a small study suggests.

“The results are impressive,” lead author Dr. Quan Dong Nguyen, from Johns Hopkins Wilmer Eye Institute in Baltimore, said in a statement. However, “we will not know until we begin a larger clinical trial what the long-term benefits of the drug might be.”

In diabetic macular edema, fluid accumulates in part of the retina responsible for central vision. Increased expression of the growth factor known as VEGF is thought to play a role in macular edema. Therefore, treatments that block VEGF, like ranibizumab, could potentially be useful.

Previous reports have shown ranibizumab to be effective in cases of age-related macular degeneration. In the present study, reported in The American Journal Ophthalmology, Nguyen’s team investigated the effects of ranibizumab in 10 patients with diabetic macular edema. The subjects were given intraocular injections of ranibizumab at the start of the study and at 1, 2, 4, and 6 months.

At the 7-month checkup, researchers noted a significant drop in macular thickness and improvement in visual acuity in study subjects.

The eye injections were well tolerated and were not associated with any side effects, the report indicates.

“We’ve suspected for a while that ranibizumab’s ability to shut down VEGF’s signaling would do the trick because it’s highly likely that VEGF is the culprit when it comes to diabetic macular edema,” Nguyen noted.

A study investigating the long-term benefits of ranibizumab for diabetes patients with macular edema is currently in the planning stage.

SOURCE: American Journal of Ophthalmology December 2006.

Print Version
comments powered by Disqus

  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  UGA ecologist finds another cause of antibiotic resistance
  Implantable ‘artificial pancreas’ could help diabetes patients control their blood sugar
  New drug for neuroblastoma shows promise in phase I study
  Baclofen shows promise in patients with alcohol-induced liver disease
  Joslin researchers find drugs are effective for diabetic macular edema in new trial
  Findings point to an ‘off switch’ for drug resistance in cancer
  New superfoods could help key protein keep bodies healthy
  Poor quality of life may affect teens’ diabetes management
  Stopping statins may benefit terminally ill patients
  Cholesterol drug users may use pills as a license to overeat
  Pfizer lung cancer drug beats chemo for previously untreated patients


Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site